MTOR and cancer: Moreover, targeting mTOR with rapamycin in the mouse model of experimental bone metastases resulted in a significant attenuation of cancer-induced osteolysis (Hussein et al., 2012; Abdelaziz et al., 2014), but had minimal effect on osteoclasts in the cancer-free bones of the same animals (Abdelaziz et al., 2015).